Marjolein van Egmond

About

Marjolein van Egmond is professor in Oncology and Inflammation. She is PI at the Department of Molecular Cell Biology & Immunology and staff member at the Department of Surgery. Throughout her career she has been fascinated by the role of antibodies in immunity and the activation of immune cells via antibody receptors (Fc receptors). Initially her research focused on the role of the Fc receptor for IgA (FcαRI) in protective mucosal immunity. Subsequently, her lab discovered that aberrant IgA initiates perpetual neutrophil activation, leading to severe tissue damage in multiple auto-immune diseases and chronic inflammation. Additionally it is now clear that antibodies can be used as therapeutic drugs to engage the immune system to fight cancer. Due to her dual appointment at a research- and clinical department, she is in an excellent position to translate experimental findings into clinical applications. Marjolein van Egmond was awarded a VENI, VIDI and VICI from the Innovational Research Incentives Scheme (Netherlands Organization for Scientific Research, NWO).

Research Line

Monoclonal antibody therapy of cancer (theme Tumorimmunology)

Because neutrophils and macrophages and have potent cytotoxic abilities we are examining whether it is possible to enlist this potential for tumour cell killing. Both myeloid cell types express Fc receptors and are, as such, able to recognize and kill tumour cells in the presence of specific monoclonal antibodies (mAbs) that opsonize tumour cells. We have demonstrated that macrophages are extremely efficient in phagocytosing and digesting circulating cancer cells in the presence of specific IgG mAbs. By contrast, neutrophils induce tumour cell death especially in the presence of monoclonal antibodies of the IgA subclass. We are currently investigating the mechanisms of neutrophil- and macrophage mediated tumour cell killing in more detail, as we anticipate that this knowledge will help us to develop novel (pre-operative) adjuvant anti-cancer therapies.

The role of neutrophil IgA Fc receptor (Fc-alfa-RI) in health and disease. (theme Mucosal Immunology)

IgA is the principal antibody in mucosal areas and plays a key role in mucosal defence. Neutrophils become highly activated when their IgA Fc receptor (FcaRI) is targeted. Since neutrophils are the first cells to arrive at inflammatory (mucosal) sites upon invasion by pathogens, we postulate that activation of neutrophil FcaRI by IgA-coated microorganisms will trigger an essential immune response that will help to clear the infection. However, aberrant IgA deposits are found in several diseases (e.g. IgA-induced blistering diseases and rheumatoid arthritis). We showed that a perpetuating inflammatory loop is initiated when excessive IgA complexes are present, which leads to sever tissue damage. We therefore aim to unravel the role of IgA- induced neutrophil activation in protective and harmful immune responses in more detail.

Figure adapted from: Aleyd E, et al. Journal of Immunoly 2016;197:4552-4559. Binding of IgA rheumatoid factor (green) to neutrophils. Neutrophils were incubated with plasma of healthy controls (upper panels) or of patients with rheumatoid arthritis (lower panels), and stained for the presence of FcRI (red) and IgA (green). Blue = nucleus.

Key publications

  1. Breedveld A, van Egmond M. IgA and FcαRI: Pathological Roles and Therapeutic Opportunities. Front Immunol. 2019; 10:553.
  2. Abis GSA, Stockmann HBAC, Bonjer HJ, van Veenendaal N, van Doorn-Schepens MLM, Budding AE, Wilschut JA, van Egmond M, Oosterling SJ; SELECT trial study group. Randomized clinical trial of selective decontamination of the digestive tract in elective colorectal cancer surgery (SELECT trial). Br J Surg. 2019;106:355-363.
  3. Grewal S, Korthouwer R, Bögels M, Braster R, Heemskerk N, Budding AE, Pouw SM, van Horssen J, Ankersmit M, Meijerink J, van den Tol P, Oosterling S, Bonjer J, Gül N, van Egmond M. Spillage of bacterial products during colon surgery increases the risk of liver metastases development in a rat colon carcinoma model. Oncoimmunology. 2018;7:e1461302.
  4. Heineke MH, Ballering AV, Jamin A, Ben Mkaddem S, Monteiro RC, Van Egmond M. New insights in the pathogenesis of immunoglobulin A vasculitis (Henoch-Schönlein purpura). Autoimmun Rev. 2017;16:1246-1253.
  5. Gül N, Babes L, Siegmund K, Korthouwer R, Bögels M, Braster R, Vidarsson G, ten Hagen TL, Kubes P, van Egmond M. Macrophages eliminate circulating tumor cells after monoclonal antibody therapy. J Clin Invest. 2014;124:812-23.

Group members

Carolien Zeelen

Carolien Zeelen, MSc

Research technician
One of the projects I work on is the optimization of circulating tumor cell detection in blood of patients using flow cytometry. The goal of this project is to see if CTCs can be targeted with antibody therapy and therefore prevent metastases. Next to that, I work on the visualization of interaction between immune cells and blood vessels in mouse tumors using fluorescent immunohistochemistry.

Celine_Sewnath

Céline Sewnath, MSc

PhD student
The focus of my work is about overcoming the immunosuppressive milieu in order to induce a potent adaptive immune response. For this, I will use new antibody therapies that will target tumor cells but also activate immune cells. Therefore, I will characterize the immune profile in colorectal cancer patients and investigate if these new antibody therapies are able to induce the adaptive immune response and thereby long term anti-tumour immunity. For this project I will use different in vitro assays on primary human cells such as RNA-sequencing data, ADCCs, ADCPs, flow cytometry, cytokine assays (Luminex, ELISA), co-cultures and in vivo work.

Gout_photo

Dennis Gout, MSc

PhD student
My main project focuses on the improvement of a neutrophil-targeting, bi-specific antibody therapy for cancers by the addition of an immuno-active payload to the antibody. I’m using these antibody-cytokine fusion proteins (immunocytokines) as a platform to attack the innate immune exclusion in various pre-clinical tumor models from multiple angles. This project involves the design, cloning and production of these immunocytokines as well as the characterization and functional testing of them both in vitro and a pre-clinical tumor model..

no-profile-picture

Kees Tuk

research technician
Main focus of my work: development of bispecific antibodies for Immunotherapy. All techniques that are necessary for this are used, mainly in vitro techniques. Mostly cell isolation techniques, Cell culture, in vitro cell function assays, ELISA’s. Also: development of in vitro assays to determine cell function of the effect of antibody complexes on cells.

JIERSOZ_FOTO_PROF

Jasmin I Ersöz

research technician
TBD

foto Leonie

Leonie Behrens, MSc

PhD student
My research focuses on the innate immune checkpoint CD47-SIRPα, which limits tumor cell killing by various myeloid cell types. My aim is to determine how SIRPα signaling prevents neutrophil activation, and how blockade of this checkpoint may improve neutrophil-mediated cytotoxicity towards cancer cells. To do so, I perform various in vitro assays to follow the different steps of tumor killing by neutrophils, e.g. formation of an immunological synapse, trogocytosis and tumor cell death.

Mandy Gruijs

Mandy Gruijs, MSc

PhD student
My research focuses on antibody therapy in cancer treatment. We have developed a bispecific antibody, which targets both a tumor antigen and neutrophils, as well as macrophages and NK cells. Additionally, I am involved in a clinical trial in which we test an already clinically used antibody in a new regimen. We have expertise in several experimental techniques, including tumor cell killing assays, flow cytometry, microscopy and ELISA.

Myrthe van Delft

Myrthe van Delft, PhD

postdoctoral researcher
The focus of my work is studying the role of IgA and FcaR1 in auto-immunity. My aim is to unravel the role of IgA induced (myeloid) cell activation in inflammation and tissue damage in auto-immune diseases (like IgA-induced blistering disease and rheumatoid arthritis). For this I make use of multicolor flow cytometry, cytokine and binding ELISAs, myeloid cell assays and mice models.

Foto Niels

Niels Heemskerk, PhD

Senior postdoctoral researcher
My research is focused on the targeting and regulation of selective immune cell trafficking across tumor blood vessels in order to improve immunotherapy of cancer by increasing the entry of antitumor immune cells in tumors.

_DSC7874_PaulaWinter

Paula Winter, BSc

research technician
My research is focused on the IgA Fc receptor (FcaRI) on neutrophils. We look at the difference between this receptor and the IgG Fc receptor (FcyR). And especially the difference in pathway it follows after activation. For this project we use several experimental techniques, including 2d migration, western blot, flow cytometry, chemotaxis and ELISA

_DSC7860_RichardvanderMast2_Lowres_sRGB

Richard van der Mast, BSc

research technician
The projects I am working on are related to antibody therapy in cancer treatment and to the role of the Fc receptor for IgA in mucosal immunity. These projects mainly focus on the role of neutrophils, macrophages and NK cells in the tumor microenvironment or inflammatory (mucosal) sites. I have experience in several techniques, including (live cell) microscopy, tumor cell killing assays, tissue stainings, flow cytometry and ELISA.

Other PI's

Jan van den Bossche

About

Jan Van den Bossche is Associate Professor at the Department of Molecular Cell Biology and Immunology at Amsterdam UMC. He leads the Translational Macrophage Immunometabolism group IMMUNOMETLAB. His young and enthusiastic team specializes in the immune/metabolic profiling and targeting of macrophages and other immune cells, particularly in the context of cancer and cardiometabolic diseas

Research Line

Our research aims to explain how metabolic reprogramming regulates macrophage subsets in different settings, focusing on cancer and cardiovascular disease. By unravelling key questions in macrophage immunometabolism, our overall goal is to demonstrate whether and how targeting macrophage metabolism could be used for future therapy.

Our distinct research lines investigate how metabolic enzymes like ATP Citrate Lyase and (immuno)metabolites like succinate and itaconate control macrophage responses and disease progression.

Metabolic rewiring in macrophage subsets
(source: Van den Bossche, O’Neill & Menon, Trends in Immunology, 2017)

Our distinct research lines investigate how metabolic enzymes like ATP Citrate Lyase and (immuno)metabolites like succinate and itaconate control macrophage responses and disease progression.

Key publications

  1. Macrophage ATP citrate lyase deficiency stabilizes atherosclerotic plaques
    Baardman, J., Verberk, S. G. S., van der Velden, S., Gijbels, M. J. J., van Roomen, C. P. P. A., Sluimer, J. C., Broos, J. Y., Griffith, G. R., Prange, K. H. M., van Weeghel, M., Lakbir, S., Molenaar, D., Meinster, E., Neele, A. E., Kooij, G., de Vries, H. E., Lutgens, E., Wellen, K. E., de Winther, M. P. J. & Van den Bossche, J., 1 Dec 2020, In: Nature communications. 11, 1, 6296.

  2. Immunometabolism in the Single-Cell Era
    Artyomov, M. N. & Van den Bossche, J., 3 Nov 2020, In: Cell metabolism. 32, 5, p. 710-725 16 p.

  3. Single-cell metabolic profiling of human cytotoxic T cells
    Hartmann, F. J., Mrdjen, D., McCaffrey, E., Glass, D. R., Greenwald, N. F., Bharadwaj, A., Khair, Z., Verberk, S. G. S., Baranski, A., Baskar, R., Graf, W., Van Valen, D., Van den Bossche, J., Angelo, M. & Bendall, S. C., Feb 2021, In: Nature biotechnology. 39, 2, p. 186-197 12 p.

 

Team

Translational Macrophage Immunometabolism group “ImmunoMetLab” – Kyra de Goede, Sanne Verberk, Jan Van den Bossche, Elisa Meinster, Karl Harber (left to right, august 2019)

Sanne Verberk’s PhD aims to target immunometabolic circuits in atherosclerotic macrophages to improve their function and disease outcome. This work is funded by a Netherlands Heart Foundation senior researcher grant.

Kyra de Goede is funded by a CCA (Cancer Center Amsterdam) PhD grant and studies macrophage immunometabolism and immunometabolites in the tumor microenvironment.

Karl Harber is appointed on a ACS (Amsterdam Cardiovascular Sciences) PhD grant and investigates immunometabolites in the context of atherosclerosis in collaboration with Prof. Menno de Winther and Michel van Weeghel at AMC.

Elisa Meinster is research technician in our group and supports distinct research lines investigating how metabolic alterations in macrophages drive their function and disease outcome. Elisa is funded by a CCA Proof-of-concept grant and an European ERA-CVD consortium grant.

Other PI's

Other PI's